A carregar...
Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
OBJECTIVES: There are no published reports for anti‐interleukin‐5 therapy in children <12 years with asthma. The primary objective of this study was to characterize the pharmacokinetics and pharmacodynamics of mepolizumab following subcutaneous (SC) administration in children 6 to 11 years‐of‐age...
Na minha lista:
| Publicado no: | Pediatr Pulmonol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6972599/ https://ncbi.nlm.nih.gov/pubmed/31502421 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.24508 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|